Posted by Michael Wonder on 02 Nov 2023
Rhythm Pharmaceuticals receives positive CADTH reimbursement recommendation for Imcivree (setmelanotide)
2 November 2023 - Recommendation based on demonstrated clinical benefit in Phase 3 trial.
Rhythm Pharmaceuticals today announced that CADTH has recommended that Imcivree (setmelanotide) be reimbursed by CADTH participating public drug plans, with conditions, for weight management in adult and paediatric patients six years of age and older with obesity due to Bardet-Biedl syndrome.
